1-7 of 7
Maximilian Stahl
Close
Sort by
Journal Articles

Intensive Induction Chemotherapy versus Hypomethylating Agents in Combination with Venetoclax in NPM1-mutant AML

Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Guillaume Berton, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D Goldberg, Eytan M. Stein, Guido Marcucci, Rebecca Bystrom, R. Coleman Lindsley, Evan C. Chen, Jorge Miguel Ramos Perez, Anthony S. Stein, Vinod A Pullarkat, Ibrahim Aldoss, Daniel J DeAngelo, Donna S. Neuberg, Richard M. Stone, Sylvain Garciaz, Brian J. Ball, Maximilian Stahl
Journal: Blood Advances
Blood Adv bloodadvances.2024012858.
https://doi.org/10.1182/bloodadvances.2024012858
Published: 2024
Includes: Supplemental data
Journal Articles

Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia

Clinical Trials & Observations
Andrew A. Lane, Jacqueline S. Garcia, Evangeline G. Raulston, Jada L. Garzon, Ilene Galinsky, Emilie W. Baxter, Rebecca Leonard, Daniel J. DeAngelo, Marlise R. Luskin, Christopher R. Reilly, Maximilian Stahl, Richard M. Stone, Rahul S. Vedula, Martha M. Wadleigh, Eric S. Winer, Tariq Mughal, Christopher Brooks, Ira V. Gupta, Kristen E. Stevenson, Donna S. Neuberg, Siyang Ren, Julia Keating, Marina Konopleva, Anthony Stein, Naveen Pemmaraju
Journal: Blood Advances
Blood Adv (2024) 8 (3): 591–602.
https://doi.org/10.1182/bloodadvances.2023011721
Published: 2024
Includes: Supplemental data
Journal Articles

FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years

Clinical Trials & Observations
Shai Shimony, Geoffrey Fell, Evan C. Chen, Harrison K. Tsai, Martha Wadleigh, Eric S. Winer, Jacqueline S. Garcia, Marlise R. Luskin, Maximilian Stahl, Donna S. Neuberg, Daniel J. DeAngelo, R. Coleman Lindsley, Richard M. Stone
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5354–5358.
https://doi.org/10.1182/bloodadvances.2023009748
Published: 2023
Includes: Supplemental data
Journal Articles

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

Clinical Trials & Observations
Maximilian Stahl, Omar Abdel-Wahab, Andrew H. Wei, Michael R. Savona, Mina L. Xu, Zhuoer Xie, Justin Taylor, Daniel Starczynowski, Guillermo F. Sanz, David A. Sallman, Valeria Santini, Gail J. Roboz, Mrinal M. Patnaik, Eric Padron, Olatoyosi Odenike, Aziz Nazha, Stephen D. Nimer, Ravindra Majeti, Richard F. Little, Steven Gore, Alan F. List, Vijay Kutchroo, Rami S. Komrokji, Tae Kon Kim, Nina Kim, Christopher S. Hourigan, Robert P. Hasserjian, Stephanie Halene, Elizabeth A. Griffiths, Peter L. Greenberg, Maria Figueroa, Pierre Fenaux, Fabio Efficace, Amy E. DeZern, Matteo G. Della Porta, Naval G. Daver, Jane E. Churpek, Hetty E. Carraway, Andrew M. Brunner, Uma Borate, John M. Bennett, Rafael Bejar, Jacqueline Boultwood, Sanam Loghavi, Jan Philipp Bewersdorf, Uwe Platzbecker, David P. Steensma, Mikkael A. Sekeres, Rena J. Buckstein, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2023) 7 (12): 2709–2714.
https://doi.org/10.1182/bloodadvances.2022008747
Published: 2023
Journal Articles

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Clinical Trials & Observations
Maximilian Stahl, Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao, Jacob Glass, Amber C. King, Anthony F. Daniyan, Christopher Famulare, Bernadette M. Cuello, Troy Z. Horvat, Omar Abdel-Wahab, Ross L. Levine, Aaron D. Viny, Eytan M. Stein, Sheng F. Cai, Mikhail Roshal, Martin S. Tallman, Aaron D. Goldberg
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1552–1564.
https://doi.org/10.1182/bloodadvances.2020003734
Published: 2021
Includes: Supplemental data
Journal Articles

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Clinical Trials & Observations
Maximilian Stahl, Michelle DeVeaux, Theo de Witte, Judith Neukirchen, Mikkael A. Sekeres, Andrew M. Brunner, Gail J. Roboz, David P. Steensma, Vijaya R. Bhatt, Uwe Platzbecker, Thomas Cluzeau, Pedro H. Prata, Raphaël Itzykson, Pierre Fenaux, Amir T. Fathi, Alexandra Smith, Ulrich Germing, Ellen K. Ritchie, Vivek Verma, Aziz Nazha, Jaroslaw P. Maciejewski, Nikolai A. Podoltsev, Thomas Prebet, Valeria Santini, Steven D. Gore, Rami S. Komrokji, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2018) 2 (14): 1765–1772.
https://doi.org/10.1182/bloodadvances.2018019414
Published: 2018
Journal Articles

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Clinical Trials & Observations
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, Raphael Itzykson, Ellen K. Ritchie, Mikkael A. Sekeres, John D. Barnard, Nikolai A. Podoltsev, Andrew M. Brunner, Rami S. Komrokji, Vijaya R. Bhatt, Aref Al-Kali, Thomas Cluzeau, Valeria Santini, Amir T. Fathi, Gail J. Roboz, Pierre Fenaux, Mark R. Litzow, Sarah Perreault, Tae Kon Kim, Thomas Prebet, Norbert Vey, Vivek Verma, Ulrich Germing, Juan Miguel Bergua, Josefina Serrano, Steven D. Gore, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2018) 2 (8): 923–932.
https://doi.org/10.1182/bloodadvances.2018016121
Published: 2018
Includes: Supplemental data